Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ovarian cancer
ovarian cancer
Merck and AstraZeneca's Cancer Drug Wins 3 New Approvals in Japan
Motley Fool
Tue, 12/29/20 - 10:57 am
Merck
AstraZeneca
Japan
ovarian cancer
prostate cancer
pancreatic cancer
Lynparza
Aspira adds slate of female execs as it launches new ovarian cancer awareness push
Fierce Pharma
Tue, 11/10/20 - 07:39 pm
Aspira Women's Health
women executives
ovarian cancer
KSQ boosts PARP inhibition in animal models of ovarian and breast cancers with USP1 inhibitor
Fierce Biotech
Sun, 10/25/20 - 11:28 pm
KSQ Therapeutics
PARP inhibitors
ovarian cancer
breast cancer
KSQ-4279
Merck
AstraZeneca
Lynparza
ESMO: Merck and AstraZeneca's 5-Year Lynparza Data in Ovarian Cancer and More
BioSpace
Sun, 09/20/20 - 08:00 pm
ESMO
Merck
AstraZeneca
clinical tirals
Lynparza
ovarian cancer
ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show
Fierce Pharma
Sun, 09/20/20 - 07:44 pm
Merck
Eisai
Keytruda
Lenvima
ovarian cancer
colorectal cancer
VBL’s ovarian cancer drug comes though interim phase 3 review
Fierce Biotech
Thu, 08/13/20 - 09:42 am
VBL Therapeutics
clinical trials
VB-111
ovarian cancer
Genentech's Tecentriq-Avastin Combo Fails to Hit Primary Endpoint in Ovarian Cancer
BioSpace
Mon, 07/13/20 - 12:15 pm
Genentech
Roche
clinical trials
Tecentriq
ovarian cancer
Clovis Oncology completes target enrollment in ATHENA trial in advanced ovarian cancer
Pharmaceutical Business Review
Thu, 06/11/20 - 11:16 am
Clovis Oncology
clinical trials
Rubraca
ovarian cancer
Opdivo
Bristol-Myers Squibb
AstraZeneca, Merck's star PARP inhibitor Lynparza expands reach in ovarian cancer with new US approval
Endpoints
Mon, 05/11/20 - 10:40 am
AstraZeneca
Merck
Lynparza
ovarian cancer
Go or no go? Oncology dominates upcoming decisions
EP Vantage
Fri, 05/1/20 - 11:09 am
FDA
oncology
AstraZeneca
Lynparza
ovarian cancer
prostate cancer
Bristol-Myers Squibb
Opdivo
lung cancer
GSK widens the market for Zejula as FDA signs off on the PARP inhibitor for use in ovarian cancer patients without BRCA mutations
Endpoints
Wed, 04/29/20 - 10:45 pm
GSK
Zejula
Tesara
FDA
ovarian cancer
Epsilogen licenses first-in-class IgE ovarian cancer drug
Pharmaforum
Mon, 04/20/20 - 10:41 am
Epsilogen
ovarian cancer
Mov18
AbbVie-backed Carisma's 'CAR-M' tech shrinks tumors in mouse models of ovarian cancer
Fierce Biotech
Tue, 03/24/20 - 10:43 am
ovarian cancer
Carisma Therapeutics
CAR-M
CAR-T
AstraZeneca and Merck's string of Lynparza successes ends in ovarian cancer
BioPharma Dive
Thu, 03/12/20 - 12:58 pm
AstraZeneca
Merck
cediranib
ovarian cancer
clinical trials
Lynparza
FDA Accepts GSK's sNDA for Zejula as a First-Line Maintenance Treatment in Ovarian Cancer
BioSpace
Tue, 02/25/20 - 04:59 pm
GSK
Zejula
ovarian cancer
FDA
AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer
Fierce Pharma
Mon, 01/13/20 - 11:49 pm
AstraZeneca
Merck
GSK
Lynparza
ovarian cancer
FDA
priority review
Zejula
Anixa delays CAR-T trial in bid to boost efficacy
Fierce Biotech
Fri, 12/13/19 - 11:00 am
Anixa Biosciences
ovarian cancer
CAR-T
FDA slaps a hold on an AML trial as Marker scraps a failing ovarian cancer program, sinking shares
Endpoints
Thu, 11/14/19 - 07:29 pm
Marker Therapeutics
AML
ovarian cancer
clinical trials
FDA
GlaxoSmithKline celebrates another Zejula win in late-line ovarian cancer — and an FDA nod for the HRD biomarker
Endpoints
Thu, 10/24/19 - 10:08 am
GSK
Zejula
ovarian cancer
FDA
PARP inhibitors
AstraZeneca strengthens lead in PARP drug class
Biopharma Dive
Sat, 09/28/19 - 05:00 pm
AstraZeneca
Merck
Lynparza
ovarian cancer
PARP inhibitors
veliparib
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »